Companies › Eupraxia Pharmaceuticals
1 active drug program in 1 registered trial: 1 Phase 1; Gastroenterology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| EP-104GI Extended-release fluticasone propionate for gastrointestinal administration | NR3C1 | Phase 1 | Eosinophilic Esophagitis | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05608681 | EP-104GI | Phase 1 | Eosinophilic Esophagitis | Gastroenterology | Dec 2026 |
Cash of $81m on 2025-12-31; operating cash outflow about $29m a year; runway about 34 months at that burn, to Oct 2028
Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.